Form 8-K - Current report:
SEC Accession No. 0001549595-26-000038
Filing Date
2026-07-09
Accepted
2026-07-09 16:09:51
Documents
12
Period of Report
2026-07-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20260709.htm   iXBRL 8-K 27392
2 EX-99.1 nrix-20260709xexx991.htm EX-99.1 99014
  Complete submission text file 0001549595-26-000038.txt   261908

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20260709.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20260709_lab.xml EX-101.LAB 23431
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20260709_pre.xml EX-101.PRE 13578
15 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20260709_htm.xml XML 2915
Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005
Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 261165775
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)